Lexaria Bioscience Full Year 2022 Earnings: Misses Expectations

Lexaria Bioscience (NASDAQ:LEXX) Full Year 2022 Results

Key Financial Results

  • Net loss: US$7.27m (loss widened by 32% from FY 2021).

  • US$1.24 loss per share.

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Lexaria Bioscience Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 25%. Earnings per share (EPS) also missed analyst estimates by 2.5%.

Looking ahead, revenue is forecast to grow 62% p.a. on average during the next 2 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 20% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Lexaria Bioscience has 4 warning signs (and 1 which is a bit concerning) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here